- Home
- PERF vs CUE Comparison
PERF vs CUE Comparison
Compare PERF & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PERF | CUE |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.6M | 233.5M |
| IPO Year | 2022 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PERF | CUE |
|---|---|---|
| Price | $1.92 | $23.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $2.98 | ★ $88.00 |
| AVG Volume (30 Days) | 176.0K | ★ 394.8K |
| Earning Date | 10-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | $7.16 | N/A |
| Revenue Next Year | $10.42 | N/A |
| P/E Ratio | $26.42 | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $1.24 | $0.17 |
| 52 Week High | $2.15 | $45.50 |
Technical Indicators
Market Signals| Indicator | PERF | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 53.49 | 38.38 |
| Support Level | $1.92 | $0.24 |
| Resistance Level | $1.95 | $33.11 |
| Average True Range (ATR) | 0.02 | 5.00 |
| MACD | -0.00 | -1.03 |
| Stochastic Oscillator | 43.80 | 5.39 |
Price Performance
Historical ComparisonAbout PERF Perfect Corp.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.